HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Clinical trials for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) trials appear
Sign up with your email to follow new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
HHT drug trial pulled before it even started
Disease control TerminatedThis study was designed to test a new drug called TER-1754 for people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds. The trial was withdrawn before enrolling any participants, so no results are available. …
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Phase: PHASE1 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated May 17, 2026 02:37 UTC
-
Could a cancer drug ease heart strain in rare genetic disease?
Disease control ENROLLING_BY_INVITATIONThis study looks at whether the drug bevacizumab can help people with hereditary hemorrhagic telangiectasia (HHT) who have severe liver issues causing high heart output and possible heart failure. Researchers will track heart function before and after treatment in about 111 parti…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated May 17, 2026 02:34 UTC
-
New drug aims to curb nosebleeds in rare bleeding disorder
Disease control OngoingThis study tests a new drug called VAD044 in 75 adults with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and anemia. The goal is to see if the drug is safe and can reduce the number, length, and severity of nosebleeds. Participants firs…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Phase: PHASE1, PHASE2 • Sponsor: Vaderis Therapeutics AG • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
New hope for rare bleeding disorder: drug shows promise in Follow-Up study
Disease control OngoingThis study follows 62 adults with hereditary hemorrhagic telangiectasia (HHT) who previously took pomalidomide in a clinical trial. Researchers are checking how well the drug controls nosebleeds and other bleeding over time, as well as its safety. The goal is to see if pomalidomi…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 07, 2026 18:39 UTC